The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Contribution of uric acid to cancer risk, recurrence, and mortality
Open accessAbstract
Two risk factors for the development and progression of cancers that are amenable to life style modification are chronic inflammation and the metabolic syndrome. This review proposes two new targets that may mechanistically integrate inflammation and metabolic syndrome, have been largely ignored, and are known to be druggable. Recent evidence has demonstrated that elevated serum uric acid (hyperuricemia) is associated with excess cancer risk, recurrence, and mortality. Although uric acid (UA) can function as a systemic antioxidant, its pro‐inflammatory properties have been postulated to play an important role in the pathogenesis of cancer. Furthermore, obesity, Type 2 Diabetes Mellitus (T2DM), and the metabolic syndrome (MetS) are also associated with excess cancer, chronic inflammation, and with hyperuricemia, suggesting that UA may represent an important link between these disorders and the development of cancer. While pharmacological modulation of hyperuricemia could in principal augment anti‐cancer therapeutic strategies, some cancer cells express low intracellular levels of the enzyme Xanthine Oxidoreductase (XOR) that are associated with increased cancer aggressiveness and poor clinical outcome. Thus, systemic pharmacological inhibition of XOR may worsen clinical outcome, and specific strategies that target serum uric acid (SUA) without inhibiting tumor cell XOR may create new therapeutic opportunities for cancer associated with hyperuricemia. This review will summarize the evidence that elevated SUA may be a true risk factor for cancer incidence and mortality, and mechanisms by which UA may contribute to cancer pathogenesis will be discussed in the hope that these will identify new opportunities for cancer management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review
Klok, M. D., Jakobsdottir, S., & Drent, M. L. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00270.x · Cited by 1,442 · cited 2×
“Thus, it has been postulated that while leptin and leptin receptor signaling act to suppress food intake and maintain long-term energy balance, the excess serum leptin found in obesity may reflect a state of leptin resistance [104].”
BackgroundPacher, P., Nivorozhkin, A., & Szabó, C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.1.6 · Cited by 1,218
Yu, M.-A., Sánchez-Lozada, L. G., Johnson, R. J., & Kang, D.-H. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328337da1d · Cited by 626 · cited 1×
“These effects were likely mediated by NADPH oxidase induced oxidative stress inside the cell [61,62,65,66].”
BackgroundSelf-citationRedox signaling and the MAP kinase pathways
Torres, M., & Forman, H. J. (2003) · BioFactors · doi:10.1002/biof.5520170128 · Cited by 580
Il'yasova, D., Colbert, L. H., Harris, T. B., Newman, A. B., Bauer, D. C., Satterfield, S., & Kritchevsky, S. B. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0316 · Cited by 479
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460
Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Nakayama, A., Ikebuchi, Y., Ito, K., Kusanagi, Y., Chiba, T., Tadokoro, S., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000237 · Cited by 437
Preitner, F., Bonny, O., Laverrière, A., Rotman, S., Firsov, D., Da Costa, A., Metref, S., & Thorens, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904411106 · Cited by 284
Panis, C., Victorino, V. J., Herrera, A. C. S. A., Freitas, L. F., De Rossi, T., Campos, F. C., Simão, A. N. C., Barbosa, D. S., Pinge-Filho, P., Cecchini, R., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1851-1 · Cited by 138 · cited 1×
“Elevated levels of CRP were positively associated with increased BC risk and risk of cancer death [36,91], and they were positively correlated with SUA levels in early and advanced stages of BC [92].”
BackgroundAlef, M. J., Vallabhaneni, R., Carchman, E., Morris, S. M., Shiva, S., Wang, Y., Kelley, E. E., Tarpey, M. M., Gladwin, M. T., Tzeng, E., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44079 · Cited by 101 · cited 1×
“Confounding problems associated with chronic inhibition of XOR include diarrhea, diminished renal function, leukopenia, hypersensitivity reactions, vasculitis [3], and even exacerbation of vascular injury through recently identified effects on nitrite reduction [153].”
Background
Cited by
Damage-associated molecular patterns in cancer: a double-edged sword
Hernandez, C., Huebener, P., & Schwabe, R. F. (2016) · Oncogene · doi:10.1038/onc.2016.104 · Cited by 480
The role of uric acid in the pathogenesis of human cardiovascular disease
Kanbay, M., Segal, M., Afsar, B., Kang, D.-H., Rodriguez-Iturbe, B., & Johnson, R. J. (2013) · Heart · doi:10.1136/heartjnl-2012-302535 · Cited by 454
Self-citationUrate‐induced immune programming: Consequences for gouty arthritis and hyperuricemia
Cabău, G., Crișan, T. O., Klück, V., Popp, R. A., & Joosten, L. A. B. (2020) · Immunological Reviews · doi:10.1111/imr.12833 · Cited by 261
Metadata
- Authors
- Fini, M. A., Elias, A., Johnson, R. J., & Wright, R. M.
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2012-08-15
- Volume
- 1
- Issue
- 1
- Pages
- 16-16
- ISSN
- 2001-1326 (ISSN-L)
- OpenAlex
- W2112164901
- Cited by
- 240
- References
- 12
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.